- Home
- ONCY vs IKNA Comparison
ONCY vs IKNA Comparison
Compare ONCY & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCY
- IKNA
- Stock Information
- Founded
- ONCY 1998
- IKNA 2016
- Country
- ONCY Canada
- IKNA United States
- Employees
- ONCY N/A
- IKNA N/A
- Industry
- ONCY Pharmaceuticals and Biotechnology
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- ONCY Health Care
- IKNA Health Care
- Exchange
- ONCY Nasdaq
- IKNA Nasdaq
- Market Cap
- ONCY 86.1M
- IKNA 79.6M
- IPO Year
- ONCY 1999
- IKNA 2021
- Fundamental
- Price
- ONCY $0.76
- IKNA $1.59
- Analyst Decision
- ONCY Strong Buy
- IKNA Buy
- Analyst Count
- ONCY 2
- IKNA 2
- Target Price
- ONCY $4.00
- IKNA $3.00
- AVG Volume (30 Days)
- ONCY 359.4K
- IKNA 99.7K
- Earning Date
- ONCY 11-12-2024
- IKNA 11-07-2024
- Dividend Yield
- ONCY N/A
- IKNA N/A
- EPS Growth
- ONCY N/A
- IKNA N/A
- EPS
- ONCY N/A
- IKNA N/A
- Revenue
- ONCY N/A
- IKNA $659,000.00
- Revenue This Year
- ONCY N/A
- IKNA N/A
- Revenue Next Year
- ONCY N/A
- IKNA N/A
- P/E Ratio
- ONCY N/A
- IKNA N/A
- Revenue Growth
- ONCY N/A
- IKNA N/A
- 52 Week Low
- ONCY $0.76
- IKNA $1.22
- 52 Week High
- ONCY $1.53
- IKNA $2.30
- Technical
- Relative Strength Index (RSI)
- ONCY 26.96
- IKNA 35.62
- Support Level
- ONCY $0.91
- IKNA $1.56
- Resistance Level
- ONCY $0.88
- IKNA $1.71
- Average True Range (ATR)
- ONCY 0.04
- IKNA 0.05
- MACD
- ONCY -0.01
- IKNA -0.01
- Stochastic Oscillator
- ONCY 11.12
- IKNA 31.58
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.